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Abstract
Background: Although renal involvement in advanced haematological malignancies is common,
glomerulonephritis associated with lymphoproliferative disorders is rare, and the related pathogenetic mechanisms
are still poorly understood. We present a rare case of chronic lymphocytic leukaemia(CLL)-associated focal
segmental glomerulosclerosis with nephrotic-range proteinuria.
Case presentation: A 53-year-old Caucasian man, previously healthy, with no history of hypertension, alcohol use
or smoking presented with rapid weight gain, massive peripheral oedema, and hypertension. Laboratory findings
included a white blood cell count of 49,800 cells/mm
3 with an absolute lymphocyte count of 47,000 cells/mm
3,
serum albumin of 2.3 g/dL, urea 65 mg/dL, and creatinine 1.5 mg/dL. A 24-hour urine collection contained 7.1 g
protein and significant haematuria. A peripheral blood smear showed mature lymphocytosis and smudge cells.
Diagnostic imaging showed mild paraaortic lymphadenopathy with no renal abnormalities. Bone marrow aspiration
and trephine biopsy showed diffuse and focal infiltration with B-CLL lymphocytes. Percutaneous renal biopsy
revealed total sclerosis in 3/21(14%) of the glomeruli and focal and segmental solidification and sclerosis in 4/21
(19%) glomeruli. A regimen of fludarabine, cyclophosphamide and rituximab was successful in inducing remission
of the CLL and clinical resolution of the nephritic-range proteinuria.
Conclusions: A multidisciplinary approach to monitor both the malignancy and the glomerular lesions is crucial
for the optimal management of paraneoplastic glomerulonephritis. Although chemotherapy with fludarabine,
cyclophosphamide and rituximab successfully treated CLL-associated nephrotic syndrome in our patient, further
studies are required to confirm efficacy in this setting.
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Background
Although renal involvement in advanced haematological
m a l i g n a n c i e si sc o m m o n ,g l o m erulonephritis associated
with lymphoproliferative disorders is rare, and the
related pathogenetic mechanisms are still poorly under-
stood [1]. Chronic lymphocytic leukemia (CLL) is more
commonly associated with membranoproliferative
glomerulonephritis and membranous nephropathy
whereas minimal change disease is the most common
paraneoplastic glomerulonephritis associated with Hodg-
kin lymphoma, followed by focal segmental glomerulo-
sclerosis (FSGS) [2]. We report on a patient with CLL
who presented with NS-associated FSGS - a rare
association.
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A 53-year-old Caucasian man, 78 kg, 1.67 cm, pre-
viously healthy, with no history of hypertension, alcohol
use or smoking, presented with a rapid 5 kg weight gain
in the past week, massive peripheral oedema, hyperten-
sion (170/90 mmHg) and leukocytosis. He had no per-
ipheral lymphadenopathy or organomegaly. A
haemogram showed a white blood cell (WBC) count of
49,800 cells/mm
3 with an absolute lymphocyte count
(ALC) of 47,000 cells/mm
3 (Figure 1), haemoglobin of
11.4 g/dL, and platelet count of 314,000 cells/mm
3.A
peripheral blood smear showed mature lymphocytosis
and smudge cells. Flow cytometry of peripheral blood
lymphocytes showed a clonal B-cell population (CD20+,
CD79b+, CD5+, CD23+, CD43+, CD11c-, FMC7-/+,
CD38-, ZAP-70 29%, ck/cl = 66) consistent with CLL
(CLL score 4). Serum albumin was 2.3 g/dL, urea 65
mg/dL, creatinine 1.5 mg/dL, cholesterol 348 mg/dL,
and beta2 microglobulin 5.39 mg/L. Hypoglobulinaemia
was present with IgG 307 mg/dL (normal range 847-
1690 mg/dL), IgA 71 mg/dL (normal range 99-300 mg/
dL), IgM 59 mg/dL (normal range 64-249 mg/L. No
monoclonal component was found in serum analysis
(serum-free chain k 22.9 mg/L [normal range 3.3-19.4
mg/L], l 16 mg/L [normal range 5.71-26.3 mg/L], k/l-
quotient 1.43 [normal range 0.26-1.65]). Urine electro-
phoresis failed to identify monoclonal protein excretion
(urine light-free chain k was 34.9 mg/L, and l was 14.2
mg/L). Kidney ultrasound showed no abnormal findings.
24-hour urine cyewqollection contained 7.1 g of protein
and significant haematuria.
A CT scan of the thorax and abdomen showed mild
paraaortic lymphadenopathy. Bone marrow aspiration
and trephine biopsy showed a diffuse and focal infiltra-
tion with B-CLL lymphocytes. Percutaneous renal biopsy
was performed with a 16-gauge needle. Twenty-one glo-
meruli were found in the biopsy cylinder. Three of the
glomeruli showed global sclerosis (14%) and 4 revealed
segmental and focal solidification and sclerosis of the
glomerular tuft (19%), (Figure 2). The non-sclerotic glo-
meruli showed mild mesangial expansion, and mild to
moderate mesangial hypercellularity. The peripheral glo-
merular capillary wall appeared normal in thickness.
The interstitium was expanded by diffuse fibrosis and
mild chronic inflammatory cell infiltrations primarily of
benign-appearing lymphocytes (Figure 3). The immuno-
fluorescence findings were negative for IgA, IgG, IgM,
C3, C4, C1q, kappa and lambda light chains. These find-
ings were consistent with FSGS.
After initial treatment with enoxaparin s.c., valsartan and
a statin, the patient received six courses of intravenous flu-
darabine (25 mg/m
2 d1-3), cyclophosphamide (350 mg/m
2
d1) and rituximab (375 mg/m
2 d1). Each cycle was given
every four weeks under continuous prophylactic therapy
with acyclovir and trimethoprim-sulfamethoxazole.
The patient showed a gradual response to therapy
(Figure 1). One month after the fourth dose, he had
complete resolution of oedema, the WBC count had
decreased to 3,500/mm
3 (ALC: 0.98/mm
3), and urinary
protein excretion had dropped to 0.7/g/day. Serum crea-
tinine was normal at 1.0 g/dL, serum cholesterol had
decreased to 195 mg/dL, and serum albumin had
increased to 4.4 g/dL. Immunoglobulin and beta2
microglobulin values were normal. After completion of
the 6 cycles of therapy, a CT scan of the thorax and
0 12 24 Months
FCR
Proteinuria(g/l)
Creatinin
(mg/dl)
White blood cells/mm3
Figure 1 Laboratory values and white blood cell count before
and after treatment with fludarabine, cyclophosphamide, and
rituximab (FCR).
Figure 2 Directly opposite to the vascular pole (double arrow),
a segmental lesion of sclerosis (single arrow) that adheres to
Bowman’s capsule, which shows significant, wrinkling (Pas
stain × 400).
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phine biopsy showed normal haematopoietic cells with-
out clonal B cells. The patient continued to receive
rituximab (375 mg/m
2 every 3 months) as maintenance
therapy for the next 24 months. At the last follow up 28
months after diagnosis the patient remains in complete
remission and the urinary protein excretion is below
200 mg/day under antihypertensive treatment.
Fludarabine, cyclophosphamide and rituximab (FCR)
therapy is becoming the frontline treatment for CLL,
especially in younger patients. These agents act synergis-
tically and are associated with high complete remission
rates and long durations of remission [3]. Focal segmen-
tal glomerulosclerosis (FSGS) is a glomerular disease
characterized by marked proteinuria, hypertension, and
a high incidence of progression to renal failure [4]. The
pathogenesis of primary FSGS remains unclear but sev-
eral observations support the hypothesis that there is a
causative factor present in the circulation of some
patients with FSGS [5]. The recommendations for initial
immunosuppressant treatment with prednisone or
cyclosporine are largely based upon small clinical stu-
d i e s .D a t ao nt h eu s eo fc y c l o p h o s p h a m i d ea n do t h e r
cytotoxic drugs for steroid-dependent or steroid-resis-
tant FSGS in adults are limited to a few retrospective
observational studies.
The alkylating agent cyclophosphamide has been pri-
mary used in children with relapsing or steroid resistant
FSGS. Rituximab is a chimeric CD20-reactive monoclo-
nal antibody with established efficacy in B-cell lympho-
mas. Binding of the antibody to the CD20 antigen
results in selective lysis of targeted B cells. Recently, sev-
eral case reports demonstrated the successful use of
rituximab in a variety of systemic diseases with renal
involvement and also in steroid resistant FSGS [6,7]. In
several recurrent post-transplant FSGS cases, NS
resolved after rituximab treatment [8,9]. Fludarabine, a
purine analogue with selective activity against both
dividing and resting lymphocytes, results in a profound
decrease in CD4 lymphocytes that may last for years.
Low-dose fludarabine treatment has been used only in
patients with membranous nephropathy [10].
Since FSGS is not an antibody-mediated disease,
improvement of NS with the FCR regime may seem sur-
prising. However, B cells play an important role as immu-
noregulatory cells through antigen processing and
presentation, recruitment of auto-reactive T cells, interac-
tion with antigen presenting cells, and secretion of cyto-
kines. B cell depletion under FCR may affect T cell
activation and downregulate the costimulation status [11].
The primary site of glomerular injury in FSGS is the
podocyte. A variety of factors have been postulated to
cause injury to glomerular cells, including circulating
cytokines such as permeability altering factor, angioten-
sin II, macrophage infiltration and other mediators of
inflammation [12,13]. Injury to the podocytes by a circu-
lating toxin is further supported by the rapidity and rela-
tively high incidence of disease recurrence in some
patients after renal transplantation. Simultaneous presen-
tation and long term remission of CLL and FSGS in our
case is consistent with the interpretation that chemother-
apy prevented the synthesis of a nephrotoxic circulating
lymphokine secreted by malignant cells. A potential para-
neoplastic link between malignancies and glomerulone-
phropathies is difficult to demonstrate, but is supported
in our patient by the parallel improvement and longterm
resolution of the two conditions under treatment.
Conclusion
A multidisciplinary approach to monitor both the malig-
nancy and the glomerular lesions is crucial for the optimal
management of paraneoplastic glomerulonephritis [2].
Although chemotherapy with FRC successfully treated
CLL-associated nephrotic syndrome in our patient, further
studies are required to confirm efficacy in this setting.
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Figure 3 Chronic interstitial nephritis, interstitial fibrosis, mild
chronic inflammation and tubular atrophy. The glomerulus here
is enlarged and shows diffuse, mild to moderate mesangial
expansion and hypercellularity without segmental sclerosis. (Masson
trichrome stain × 200).
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